C
Cyrus Biotechnology
Advanced computational software for protein modeling and design
About Cyrus Biotechnology
Cyrus Biotechnology is a cutting-edge startup based in Seattle, specializing in advanced protein engineering and computational biology. The company primarily serves clients in the biopharmaceutical, synthetic biology, chemical, non-profit, academic, and consumer product sectors. These clients range from large pharmaceutical companies developing new drugs to academic researchers studying protein structures.
Cyrus operates in the highly specialized market of protein design and optimization. The company uses sophisticated computational methods to solve complex problems in protein engineering, such as protein stabilization, difficult protein structure prediction, and enzyme optimization. Their services are crucial for clients looking to bring new products or drugs to market faster and more efficiently.
The business model of Cyrus Biotechnology is flexible and client-centric. They offer a variety of solutions tailored to the specific needs of their clients. This includes partnership models where they share risks and rewards with their clients on well-defined projects, as well as independent project support where clients can use Cyrus's tools and expertise to achieve their goals.
Cyrus makes money by providing these specialized services and solutions. They charge fees for their computational tools, consulting services, and collaborative projects. By helping their clients solve difficult protein-related problems, Cyrus adds significant value, enabling faster and more cost-effective development of new products and therapies.
In summary, Cyrus Biotechnology leverages advanced computational methods to assist a diverse range of clients in the biopharma and related industries, offering flexible business models to meet varied needs.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 64.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Modeling, Developer Tools, Biotechnology, Molecular, Synthetic Biology, Spinout, Macro-Nutrients
- Technology
- Deep Tech
- Business model
- Manufacturing, SaaS
- Client focus
- B2C
- Investment activity
- 1 company, latest Dec 2021
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Dec 2021 | $18M | $72M | Family Offices Today · The Yard Ventures · iSelect Fund · Selecta Biosciences | ↗ |
| LATE VCEquity / VC | Jul 2021 | $16M | $64M | Undisclosed | — |
Growth signals
Latest recorded traffic for Cyrus Biotechnology is 3K monthly website visits, down 25% over the last three months. Cyrus Biotechnology's team declined 29.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Cyrus Biotechnology in the Seattle ecosystem
The Cyrus Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
WINGS
The W Fund
Series A8 investors entered at this stage
Trinity Ventures
SpringRock Ventures
OrbiMed
Family Offices Today
The Yard Ventures
iSelect Fund
Selecta Biosciences
Agent Capital
Other known investors4 additional known investors
University of Illinois Urbana Champaign
University of Washington
Alumni Ventures
Sahsen Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cyrus Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cyrus Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








